Глобальный журнал биологии, сельского хозяйства и медицинских наук

Абстрактный

EARLY PREDICTION OF LIPID DERANGEMENT DURING ANTIPSYCHOTIC (OLANZAPINE) TREATMENT

Amita Gupta, Dr.S.B.Petkar, Dr.Aashish Jadhav & Dr.Vaibhav Dubey

Background: Earlier studies have demonstrated the relationships of lipid levels with psychiatric patients taking atypical antipsychotics, and their results revealed an association between hyperlipidemia and antipsychotic treatment. The present study was undertaken to evaluate the lipid profile alteration after 16 weeks of treatment with Olanzapine and compare with normal subjects. Material & Methods: This study was conducted at Department of Psychiatry & Department of Biochemistry People’s College of Medical Sciences and Research Centre, Bhopal. Thirty newly diagnosed patients, who completed 16 weeks of treatment were included and compared with 40 healthy subjects. In our study we have measured lipid profile which includes serum total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), very low density lipoprotein cholesterol (VLDL), and cardiovascular risk factors (R1&R2) & Body mass index (BMI). Results: The concentration of TC, TG,LDL and VLDL and risk factors were increased, whereas HDL was decreased after 16 weeks of Olanzapine treatment (p<0.05). Conclusion: In view of the relationship between antipsychotics (Olanzapine) and lipid derangement, it is clearly evident that lipid parameters and risk factors for coronary heart disease are significantly altered after Olanzapine treatment.